Remove 2027 Remove Disease Remove Marketing
article thumbnail

How point-of-care technology providers can drive market growth with liquid handing instruments

Tecan

By Joe Guterl More than $72 billion – that is what some researchers estimate will be the global point-of-care (POC) biochemical diagnostic testing market size in 2027, up from $36 billion in 2021.

article thumbnail

PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE UNTIL MARCH 2027

The Pharma Data

RE47,739 (‘739) by more than four years until March 5, 2027. Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with CDK4/6 inhibitors, including IBRANCE when taken in combination with endocrine therapy. The certificate extends the term of U.S. 2,3 In the U.S.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Biotech Startup Contraction Continues… And That’s A Good Thing

LifeSciVC

Fundamentally, even during tighter markets like today, great talent is always a very constrained resource, and spreading it too thinly across too many companies isn’t good for the ecosystem. Overall, this contraction is a strong positive sign of healthy discipline, and should be good for the sector’s mid- and long-term prospects.

DNA 110
article thumbnail

Proposed LDT Rule Raises Many Questions but Provides Few Answers

FDA Law Blog: Biosimilars

The amended regulation would read as follows (revisions underlined): In vitro diagnostic products are those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae.

article thumbnail

AI-Designed Drugs vs. Traditional Drug Discovery: Pros and Cons

Vial

This is evident in the estimated market value for AI in drug discovery, which was US$0.6 billion by 2027 , at a compound annual growth rate (CAGR) of 45.7% This acceleration of the drug discovery process could potentially save countless lives by bringing effective treatments to market more quickly. between these years.

Drugs 52
article thumbnail

Lilly Announces the Pricing Terms of Its Cash offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities

The Pharma Data

5.500% Notes due 2027 532457 AZ1 7 0.750% due August 31, 2026 0.820% 40 bps $1,226.23 3.100% Notes due 2027 532457 BP2 13 0.750% due August 31, 2026 0.820% 35 bps $1,100.66 5.500% Notes due 2027 532457 AZ1 7 0.750% due August 31, 2026 0.820% 40 bps $1,226.23 and Citigroup Global Markets Inc. BNP Paribas Securities Corp.

Disease 52
article thumbnail

AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS

The Pharma Data

S&P Global Ratings provided the second party opinion on the Framework and reported that it is aligned with the Green Bond Principles (2021) administered by the International Capital Market Association. “This green bond will fund specific projects across our company that are intended to mitigate our impact on the environment.”